
BCTX Stock Forecast & Price Target
BCTX Analyst Ratings
Bulls say
BriaCell Therapeutics Corp has demonstrated a strong commitment to advancing its immunotherapy programs, highlighted by the recent award of a non-dilutive $2 million grant from the US National Cancer Institute (NCI) to enhance the manufacturing of Bria-PROS+ and support its Phase 1/2a development for metastatic prostate cancer. This financial backing not only reflects confidence in BriaCell's innovative approaches but also positions the company to expedite the clinical development of its personalized off-the-shelf therapeutic platform, Bria-OTS+. Furthermore, BriaCell's ongoing focus on developing targeted immunotherapies for breast cancer, combined with its strategic collaborations for combination therapies, underpins a robust outlook for the company’s growth potential in the competitive biotechnology landscape.
Bears say
BriaCell Therapeutics faces significant risks that contribute to a negative outlook, including the potential for adverse safety signals from its clinical and preclinical programs and challenges related to achieving expected efficacy in trials. The company is projected to require approximately $120 million in additional financing by 2037, with further capital needs anticipated in fiscal year 2026, adding pressure on its financial stability. Additionally, the company faces increasing commercial competition and regulatory uncertainties that could hinder its product development and market entry.
This aggregate rating is based on analysts' research of BriaCell Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
BCTX Analyst Forecast & Price Prediction
Start investing in BCTX
Order type
Buy in
Order amount
Est. shares
0 shares